text:
ICU Medical (NASDAQ:ICUI)
Q2 2014 Earnings Call
August 11, 2014 4:30 pm ET
John Mills - Partner
Vivek Jain - Chairman and Chief Executive Officer
Scott E. Lamb - Chief Financial Officer, Treasurer and Secretary
Thomas J. Gunderson - Piper Jaffray Companies, Research Division
Chris Lewis - Roth Capital Partners, LLC, Research Division
Jayson T. Bedford - Raymond James & Associates, Inc., Research Division
L. Mitra Ramgopal - Sidoti & Company, LLC
Lawrence Solow - CJS Securities, Inc.
James Terwilliger
Good day, ladies and gentlemen, and welcome to the ICU Medical Conference Call Second Quarter 2014 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to John Mills. Sir, you may begin.
John Mills
Great. Thank you. Good afternoon, everyone. Thank you for joining us today to review ICU Medical's financial results for the second quarter ended June 30, 2014. On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman; and Scott Lamb, Chief Financial Officer. Vivek will start the call with a brief overview and then Scott will discuss second quarter financial performance, and provide financial guidance for the third quarter and full year of 2014. Finally, the company will open the call for your questions.
Before we start, I want to touch upon any forward-looking statements made during the call, including management's belief and expectations about the company's future results. Please be aware they are based on the best available information to management and assumptions that management believes are reasonable. Such statements are not intended to be a representation of future results, and are subject to risks and uncertainties.
Future results ma y differ materially from management's current expectations. We refer all of you to the company's SEC filings for more detailed information on the risks and uncertainties that have a direct bearing on operating results and performance and financial conditions.
Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. We believe these adjusted financial measures can facilitate a more complete analysis, and greater transparency into ICU's ongoing results of operations, particularly in comparing underlying results from period-to-period.
We have included reconciliations of these non-GAAP measures with today's release, and have provided as much detail as possible on any adjustments that are added back.
With that said, I'll now turn the call over to Vivek Jain. Go ahead, Vivek.
Vivek Jain
Thanks, John. Good afternoon, everybody. Hopefully, we'll have a quick call today. With one full quarter start to finish here under my belt now, I think we can start providing some more details on the plans we started to lay out on previous calls.
Our second quarter results were better than expected. We generated strong cash flow and adjusted EBITDA, and we're adjusting upwards our guidance ranges for adjusted EBITDA and EPS and GAAP EPS for 2014. The revenue mix was a little bit different than expected, and we'll provide more color on that momentarily. Our second quarter largely resembled what's been going on here all year through today. Strong performance in all of our direct operations, with good growth in our direct U.S. infusion, oncology and critical care businesses, and all of our direct businesses internationally, in total, leading to 7% growth year-to-date on a direct basis. These gains have largely been offset by a 12% year-to-date decrease in our OEM results, as our channel partner continues to work to improve its current position.
On the February and May calls, I laid out what I believe are the core value drivers for ICU Medical, which in summary are based on, one, our manufacturing scale in the needlefree connector category; two, the sticky nature of our products; and three, our strong balance sheet and cash-generating ability.
On the May call, I tried to bookend 2 basic scenarios, both of which I believe generate improved value creation relative to where we are today. Those scenarios were framed as: in the best case, we'll have better execution to improve our top line performance, responsibly deploy capital, drive operational improvements and explore returning capital to shareholders to the extent it makes sense. In the worst case, we continue to fight headwinds on the top line, but we can still drive operational improvements and more actively explore returning capital to shareholders.
I also talked about where I felt it will be possible to improve our execution with just some operational rigor in the short- to medium-term. I continue to believe ICU is a company that is big enough to be big and small enough to be small. We're a big player in the infusion therapy category and can expand our global reach, but we have an income statement that is able to be influenced quickly.
Just some basic decisions can make a meaningful improvement on our P&L. And we said we were keenly aware of when these activities had to start to fully make it into the 2015 fiscal year, as we focused on improved performance for next year.
I wanted to first give an update of where we are for these improvements, and give some context to the other parts of the plan that affect the balance of the year and the items that we can hopefully be talking about later in the year. So I wanted to start with the 2 items that we control the most directly: improvement in our direct commercial operations; and driving operational leverage.
As I dove deeper into ICU Medical in the first few months, it became increasingly clear to me that we lacked direct commercial scale in the U.S. around our key product lines of needlefree connectors, sets and oncology products; that we lacked basic selling infrastructure in the international market and they desperately need feeding given the growth; and we diluted our efforts with a substantial amount of resources directed to either less value creating markets or products, whose channels could be managed more centrally. And we had a number of non-value-added activities happening around the company, where resources could be deployed to more urgent needs.
I guess I'd call this the inevitable growing up of the company that we needed to do, as we tried to diversify our revenue sources and market exposure, and I understand it's a hard reality for homegrown companies, whose formula worked well for the first 90% of its -- of their existence. A few weeks ago, we made a series of changes to our selling and corporate infrastructure. We redirected resources towards our core hospital customers in the U.S. with a combined single bag of all of our infusion and oncology products with a larger number of reps, with smaller territories, allowing for more focus towards our customers. And we've been actively recruiting for our international markets, and new team members will be joining the company to help us expand internationally.
Lastly, we put all of the assets, people infrastructure, into very separate measurable teams for infusion therapy, critical care and international, where performance and returns can be tracked closely. We funded these changes largely through the elimination of about 15% of our nonmanufacturing headcount.
On the last call, I talked about at least $10 million of SG&A improvement as our goal for fiscal year '15 versus fiscal year '14. These changes go a long way into meeting that goal. On top of that, we see many additional operational improvements that come from just running ourselves wisely and being extremely, extremely careful how we spend. We're also heavily investing in R&D in fiscal year '14, and should see decreases heading into fiscal year '15.
These items are beyond the $10 million improvement, but we do not want to quantify them at this time. Because we think about these cost savings as the net improvement for fiscal year '15, if our OEM situation does not improve and as the funding sources to handle any additional revenue challenges or potential bumps for the balance of the year.
It's important to note, over the long term, cost savings are absolutely not the answer for ICU Medical, but they are necessary today to get us prepared for the future. We have to grow, and it's about trying to improve our commercial execution and grow our sources of revenue. I've been involved with changes like this in prior experiences that have been very successful, but it is often bumpy for a while after the changes, so we wanted to make sure we got to them as soon as possible.
The other item we talked about on previous calls was the prolonged transition period that the company was in during fiscal year '12 and fiscal year '13, and some of the downstream effects when the company didn't make the marginal investment, as it was unsure of its long term. I hope we can stop talking about that, as we head into fiscal year '15, as the company moves much more to a culture of accountability and urgency. But I wanted to remind everyone, as I have said in previous calls, there are remaining core areas that we need to solidify with investments and onetime costs into quality, certain technical competencies, and a little bit of infrastructure to be able to deploy capital. I've not yet fully flushed out all those areas, and I need to.
The last comment in this transition period is that it likely reached its peak during Q3 of fiscal year '13 and as a result, our Q3 revenue year-over-year comparisons will likely look the most skewed.
I hope on the next few calls, we can begin to talk about the other parts of the plan. We believe we will see a reduction in capital expenditures for next year, helping to continue strong free cash flow generation. We know we need to address capital deployment and/or capital return and we would like to be able to spend time to of those topics. And ultimately, we want to be talking about new products, and the returns we desire on our R&D investments. But we're not ready to do that for another few quarters.
Shifting back to the current quarter, we're pleased on all of our direct operations. Obviously, we have talked on previous calls about the landscape in U.S. infusion being a temporal situation, and we saw encouraging steps regarding our partners product status announced publicly recently, and are qualitatively pleased with the focus our partner is bringing. That said, we continue to be appropriately cautious, and we did see a divergence in the oncology product line. As a reminder, our oncology products are sold on a direct basis and through our OEM partner.
And in Q2, our direct oncology business grew 9%, while our OEM oncology business declined 14%. This is not a metric we intend to disclose regularly, but felt it was worth mentioning now. To be clear, our direct business is approximately 65% of our oncology total. And today, we have a much larger sales force calling on it, as we effectively doubled the number of reps focused on these products, with our recent changes.
As a result of the recent divergence and the changes in our sales force, broadly, we are not going to provide quarterly revenue guidance by market segment. Rather, we're going to provide segment guidance annually, and update total revenue guidance quarterly, unless other significant changes occur.
As I've said on previous calls, there are a lot of positive drivers, and the scenarios are coming together as we now enter the execution stage. I have a lot of confidence in the long-term value creation, due to our increasing global reach, our ability to renovate and reprioritize, our strong balance sheet and our willingness to make change.
We are trying to take responsible action and break some of the inertia that many companies in our position face. In the short term, we'll have some bumps and we will overcome them and emerge stronger for fiscal year 2015. On our next call, we will provide you with more color on the additional parts of the plan, and how they will improve our overall returns.
With that, I'll turn it over to Scott.
Scott E. Lamb
Thanks, Vivek. Before I begin, let me remind all of you that the sales numbers we are covering, as well as our financial statements, and a reconciliation from our GAAP to adjusted EBITDA and EPS are available on the Investor portion of our website for your review.
As we have explained in recent conference calls, during the past two quarters, we have been evaluating comparable medical device companies, and saw the majority of these companies were providing adjusted financial measures. We have completed our review, and going forward, we will continue to report adjusted earnings per share and adjusted EBITDA. We believe that by doing so, we will provide a better view of our earnings, as we begin to exit our transition period.
Going forward, we will provide as much detail as possible on any adjustments. Those key adjustments we are talking about include items, such as stock compensation expense, restructuring and possession related costs.
So now, on to reporting our Q2 results. Our second quarter results were driven primarily by strength in our international and U.S. direct sales. Total revenues were $79 million in the second quarters of 2014 and 2013. Second quarter 2014 adjusted EBITDA was $16 million compared to $18 million last year. The decline was primarily due to increased R&D expenditures and a slight decrease in gross margin.
Adjusted diluted earnings per share for the second quarter 2014 was $0.51 compared to $0.58 last year. GAAP net income for the second quarter was $6 million or $0.38 per diluted share, as compared to GAAP net income of $7 million or $0.48 per diluted share last year. The decrease was primarily due to a noncash-based stock compensation expense and increased R&D.
Now, let me discuss our second quarter revenue performance by market segment. You can also view our detailed market segmentation in our earnings press release. For the second quarter, sales in infusion therapy decreased 2% to $55 million and represented 70% of our total sales. International infusion therapy sales increased 13%. U.S. direct sales increased 4%, but were more than offset by a 12% decrease in U.S. OEM sales.
Sales in oncology were flat year-over-year at $9 million, which represented 12% of revenue. An increase in our global direct sales of 9% was offset by a 14% decrease in our OEM sales. And as Vivek already mentioned, we are addressing oncology through our restructuring efforts, and we will continue to focus on this growth area of opportunity. Sales in critical care increased 8% to $14 million and represented 17% of our sales. Sales grew across all geographies.
Our second quarter sales for direct and OEM were as follows: direct sales were up in all geographies and all market segments; on a global basis, direct sales increased 10% from $46 million to $50 million; OEM sales decreased in both infusion and oncology; and on a global basis, OEM sales decreased 13% from $33 million to $28 million.
Now our second quarter sales for domestic and international were as follows: domestic sales were down 4% to $55 million for the second quarter compared to $57 million for the same period last year. The primary reason for this decline was lower OEM U.S. infusion therapy and oncology sales.
International sales were up 12% to $24 million compared to $22 million last year. This increase was driven by improved direct sales of infusion therapy, oncology and critical care. Our gross margin for the second quarter was 47.7% compared to 48.4% last year, and primarily reflected an increase in critical care sales, and less infusion therapy sales.
SG&A expenses increased to $24 million compared to $23 million last year, primarily due to higher noncash stock compensation expense. Due to the restructuring Vivek spoke about, we will begin to see a decrease starting this quarter. Also, we expect a restructuring charge of approximately $3 million in the third quarter, which may increase over the balance of this year.
Our research and development expenses increased 17% year-over-year to $5 million, as we continued to invest in organic growth opportunities in all of our primary market segments, and in particular, critical care.
As we stated on our first quarter call, we will continue to invest in innovation and new products throughout 2014. This will be an all-time high of R&D spend on an absolute dollar basis. And starting in 2015, we expect this to decline.
Now moving to our balance sheet and cash flow. As of the end of June, our balance sheet remained very strong, with no debt. We generated $16 million of operating cash flow, and increased our cash, cash equivalents and investment securities to $316 million. This equates to approximately $21 per outstanding share.
Now let me update you on our third quarter and full year guidance for 2014. For the third quarter, we expect revenues to be in the range of $70 million to $75 million. For the year, we expect to be in line with our previously issued guidance of $285 million to $300 million. For the third quarter, we expect our adjusted EBITDA to be between $14 million and $17 million, and our adjusted diluted earnings per share to be between $0.41 and $0.52, and GAAP earnings per share to be between $0.13 and $0.24.
We are raising our previously announced annual expectations for adjusted EBITDA, EPS and GAAP EPS as follows: our adjusted diluted earnings per share for 2014 to be in the range of $1.95 to $2.15. We are raising our adjusted EBITDA for the full year to now be in the range of $63 million to $68 million compared to the previous range of $58 million to $65 million.
We expect GAAP diluted earnings to be in the range of $1.30 to $1.50 compared to the previous range of $1.15 to $1.45. And you can find a reconciliation of these metrics in our press release and on our website.
We expect gross margins to be approximately 49%, and we expect SG&A to be approximately 32% of revenue, excluding any restructuring charges. We also expect research and development spend to be approximately 5% of revenue. And for modeling purposes, we expect our tax rate to be approximately 34%. In addition, we expect our CapEx spend to be $16 million to $19 million this year and to start declining in 2015.
Now before we open up for questions, I would like to say that I've been CFO here now for 6 years. And the changes over the last 3 months and how we are examining our cost infrastructure, and how we are developing and executing on long-term plans, has been the most activity that we have had in my tenure. Overall, our team is very excited about the positive changes we are implementing throughout our organization.
And with that, I would like to turn the call over to your questions.
Question-and-Answer Session
[Operator Instructions] And the first question is from Tom Gunderson of Piper Jaffray.
Thomas J. Gunderson - Piper Jaffray Companies, Research Division
I just have 2 questions, I think, 2. One is the direct sales revenue were up -- or revenues were up in that sector, and you attribute it appropriately, but there's a lot of things that go into that, especially when you're realigning sales forces and assignments, et cetera. Was there anything among that bag of things that can contribute to higher revenues through direct sales that you saw come out more forcefully than the others?
Vivek Jain
Tom, do you want both parts of the question? Or you want us to answer the first one first?
Thomas J. Gunderson - Piper Jaffray Companies, Research Division
Oh, and --yes, -- now the second part the question is smaller and that is the sales force realignment. We've seen a lot of these, investors have seen a lot of these in the last 12, 24 months. Sometimes they go well, sometimes, not so well. Can you give us a sense of the percentage of territory disruption with all the changes that you talked about?
Vivek Jain
Sure, sure. So let me take those in kind of reverse order. On the direct sales impact of the changes on the quarter, these activities went into place after the quarter ended, hence our call actually being a little bit later than I'd ideally like. So I don't know if there was any impact of that on Q2. There are really changes to set up for the long-term. So there was nothing in it that affected Q2. And just to be more granular about it, international has been actually the fastest-growing part, not domestic. All of these changes are really domestic. We're going to be adding to international, but that hasn't happened yet. So it's been o U.S. that's faster. I've been through some of these sales force redefinitions in previous lives. I think this was more marginal here. We had a sales force focused on what -- when I was in the script talking about lower value segments, a lot of stuff in places where it's hard to cover with a direct sales force, alternate site, et cetera. We just eliminated a lot of those territories and their -- added a few new territories. So on the margin, it's not a wholesale revamping, it's more on the edges of each person's territory.
Thomas J. Gunderson - Piper Jaffray Companies, Research Division
Got it. And on the components of growth, was there large customer focus? Small customer focus? Reorders? What kind of things where you looking at that gave you the extra boost?
Vivek Jain
On the direct business, there are no large customers, so to speak, right? Our direct business is -- in the U.S., 450 different IDNs make up 90% of our business, so there's not one particular customer that's out of line, and the same thing's true for international, whether we're direct or using a local distributor, no one person accounts for a disproportionate amount of sales, unlike the OEM relationship that we have.
Thomas J. Gunderson - Piper Jaffray Companies, Research Division
But was there anything that surprised in the quality of the quarter? On the sales of what you had that give you a little bit larger number than...
Vivek Jain
Again, I think, if there -- I'm sorry, I should have answered that more specifically. I think the critical care number was a bit of a surprise on the upside for us on a direct basis. That's also been true for the previous quarter. I'd say year-to-date in critical care.
The next question is from Chris Lewis of Roth Capital Partners.
Chris Lewis - Roth Capital Partners, LLC, Research Division
I think you mentioned 15% headcount reduction. Can you just talk about where those cuts were made across the organization?
Vivek Jain
Sure. I don't want to get into too many specifics. I would say a lot of the changes came out of -- kind of these lower market opportunity selling organizations that we had, that just address kind of smaller markets than our core hospital market, as well as a number of kind of corporate in-between-the-business kind of jobs that don't necessarily need to exist if we run ourselves in more vertical-oriented businesses. So I'd say the majority out of smaller sales teams and the remainder out of the corporate center.
Chris Lewis - Roth Capital Partners, LLC, Research Division
Okay. And then on the OEM channel, can you just maybe walk us through in a bit more detail what you're seeing from Hospira now? Has that improved? Stayed about the same? Or potentially declined since, I think, maybe, you came on board and going forward? It sounded like some of your prepared remarks were a little more positive than they were 3 months ago. So maybe just talk us through your expectations for that segment over the next 12 months?
Vivek Jain
Sure. Again, in the beginning of the year, right when I got here, the trend with our OEM partner was not great. They're really working hard on improving where they are. I think the rate of decrease has been substantial in the first 2 quarters of this year. You can see that in the year-over-year comps. I think what I care about is are they -- is the curve flattening out sequentially? Is it becoming more normalized? It is becoming a bit more normalized, but we are being cautious. I mean this thing on oncology was a bit of a divergence than we thought. And you heard maybe that -- in the last quarters' comments that we were taking another look at that. I think it's appropriate for what we've seen. You can look at the publicly reported pump companies' results. I think just as we said at the beginning of the year, we are planning for it to potentially be bumpier in the back half, and I think that's the right kind of frame of mind, and the right way to price out our own infrastructure as a company, if we make that assumption today.
Chris Lewis - Roth Capital Partners, LLC, Research Division
And then, for your revenue guidance, I think if you just annualize the first half of the year, it gets you above the high-end of the guidance. So walk us through the expectations for the remainder of this year, and why you didn't bring that expectation up?
Vivek Jain
Really, 2 reasons. One is the question you just asked on what's going on with our OEM partner, right? We want to make sure we're being appropriately cautious there. The changes over the last 2 or 3 years really surprised ICU, for lack of a better word, and I want to make sure we're thinking about that right. And the second reason is we just tinkered with our selling organization, and that always leads to a little bit of bumps, and I want to make sure we are being mindful of that too. I don't think there's any other science in it behind that. As I said when I got here, I really cared about cash flow and we're focusing on what drives cash in the short-term. And over the long term it's absolutely about revenue growth, that's what we should be talking about. We're just not quite there yet.
Chris Lewis - Roth Capital Partners, LLC, Research Division
Great. And then, just on the M&A front, can you talk about the appetite there, potential markets or products you think would be most attractive and the best fit for the company.
Vivek Jain
I would generalize that answer and just say, "Look, you feed what is working" and what is working for us is the international opportunities right now. And to the extent there's an opportunity to put capital to work to keep broadening that, I'm not a big believer in jumping 3 steps up the stairs at once, right? It has to have some value with what we do as a manufacturing company or some value to what we do from a channel perspective. And if it fits with one of those and it's international, I think we're more interested in looking at it. I think the odds of finding an attractive deal that fits those parameters domestically is probably pretty low, to be candid.
The next question is from Jayson Bedford of Raymond James.
Jayson T. Bedford - Raymond James & Associates, Inc., Research Division
I guess maybe, Vivek, can you just talk about the changes in the U.S. selling team? I guess, can you frame what the organization looked like from a number of reps and a focus versus what it looks like today?
Vivek Jain
Sure. We had 4 or 5 different U.S. sales forces, all organized in different parts of infusion therapy. So that's kind of what it was at the highest level. We had a number that I felt was woefully subscale on oncology, and a number of heads that was woefully subscale in core hospital, so regular old, up the middle U.S. hospitals. By combining that group of oncology and hospital people and adding some funding to it -- create new positions, we get to a headcount that I find more acceptable to call on U.S. hospital with. I don't know what the end state looks like, but it's some number that's 40-ish, 40-plus people doing that -- I would say, in oncology or in core hospital, we had on the range of 20 people or less than 20 people calling on some of those markets. And that's just -- it's too small to cover the country effectively.
Jayson T. Bedford - Raymond James & Associates, Inc., Research Division
I'm sorry, on a net basis, did you add to the U.S. team? And if so, by how much?
Vivek Jain
On a net basis, we will be down in heads because we removed some of our smaller sales forces to U.S. hospitals. We will have more people calling on core IV products and oncology products than we've had before. So we will have, as I said in the prepared remarks, in oncology, we'll literally have double the amount of people calling than we had before. But some of those people were with the company already, right, a part of the hospital team.
Jayson T. Bedford - Raymond James & Associates, Inc., Research Division
And just, I guess, from a market perspective, in oncology, how quickly do you think that category is growing?
Vivek Jain
I think it's a different answer, depending on where you are in the world. Europe and certain part -- the high-value parts of other geographies have actually been ahead of the U.S. on a value of closed-system transfer devices. And so, I think the fastest growth is actually Europe, and then certain parts of Asia. The U.S. is probably behind that. I think the U.S. is easily a 5% to 10% growth market, if not better, and the international markets are double-digit growth markets.
Jayson T. Bedford - Raymond James & Associates, Inc., Research Division
Okay. That's helpful. And then maybe, Scott, can you comment on gross margin? I realize there's probably a mixed dynamic here with critical care, but just even looking at the business -- and this maybe too shortsighted, but looking at it sequentially, revenue was up, critical care was a bit more, but gross margin took a step back. And I'm just wondering, if you can just walk us through the weights on margin this quarter?
Scott E. Lamb
Yes, again, it was primarily driven by -- you already mentioned. We were down in infusion therapy, 2%. We were up in critical care. And as we've said on previous calls, our critical care has an average gross margin that's south of the corporate average. So that, in combination with a very small, one-time charge in the second quarter, that brought our gross margins down. And I think that mix going forward for the remainder of this year will help keep margins at approximately a 49% range.
The next question is from Mitra Ramgopal of Sidoti.
L. Mitra Ramgopal - Sidoti & Company, LLC
First, Vivek, you mentioned one of the things you identified was the international markets sort of lacked the infrastructure that it needed. How a long of a process do you think that will take in terms of getting it up to where you would like it to be?
Vivek Jain
It depends how much we can do with organic investment, and that's why we have to free up P&L dollars to make those investments. It's the one thing we control in playing the cards that we have. The other thing that can accelerate it is if you can allocate and deploy capital to do some of the international opportunities. So let's leave the second one off for the time being, say we can't find good areas to deploy capital. I don't believe that's the case, but for arguments sake. Just to get some people and a team ramped up and effective in a country, it takes 6 months, 9 months, some amount of time. So again, I wish it was running and ready to go tomorrow, but if we don't start today, it's only more time wasted. So I think we're really trying to set up the world for the future growth, '15, '16 and beyond. We've got to get the people that we need in here today, just like we've got to fix and give the U.S. teams the best chance to execute commercially today, all right? And then if we could supplement within organic, we'll do it. But we can't count on that.
L. Mitra Ramgopal - Sidoti & Company, LLC
And again, the focus is mostly Europe or is it also Asia?
Vivek Jain
Asia is actually the fastest-growing region for us by a long way. It's amazing to me what the team here has been able to cultivate [indiscernible] distribution relationships and a very small direct operation with a limited number of people in Asia. It's really amazing.
L. Mitra Ramgopal - Sidoti & Company, LLC
And coming back to the critical care segment, I know it exceeded expectations a little. Are we seeing the new products having an impact yet? Or is that without new products?
Vivek Jain
Nothing, no new products. I mean those are what -- a lot of the big R&D spend is going on right now. And candidly, as I said in the last call, we haven't really tinkered with critical care very much. So I'm glad that we've found kind of the natural state here for at least 2 quarters in a row, but part of the question -- the previous question as to why we are still being cautious on the back half of the year, is we just don't necessarily see the underlying demand trends in critical care footing up to what's going on, so it's probably better to be cautious about that right now.
L. Mitra Ramgopal - Sidoti & Company, LLC
And finally, I think you had mentioned R&D, we should see the spending sort of come down a little starting 2015. That's really a sense that you feel comfortable that the investments you've made this year, you'll be pretty much able to roll out the products, et cetera, and you just don't need to invest as much?
Vivek Jain
Well, I think in the dream world, right, you'd love to have as much money as you'd like to invest there. I think the company has invested heavily last year and this year, and we've kind of taken stock of the programs that are in right now. How much can we push through and get done as fast as we possibly can? And that's kind of the mentality that, that team is running with right now. And so we are not putting any constraints, candidly, on what they're doing. We want to see stuff get finished this year, if possible. Even if that means they don't properly launch, get into the market, et cetera, to the middle of next year, the bulk of the spend items, the testing, the trials, et cetera, let's get them done right now. I'm not a huge one to kind of worry about what's the right percentage of sales in R&D. I mean, I can make the argument our OEM revenues ought to be excluded from that calculation to get to the right metric. But I don't think this is -- like, the company is not big enough where those percentages matter, it's just the absolute amount of dollars to keep infusion therapy or oncology going once the critical care spend comes off.
[Operator Instructions] And the next question is from Larry Solow of CJS Securities.
Lawrence Solow - CJS Securities, Inc.
Vivek, last quarter you mentioned it may be necessary to build a little of your infrastructure out in terms of readying yourself to have a better ability for integration of acquisitions. Have you made any steps to -- on that front?
Vivek Jain
I think we've made the internal operational steps, in terms of getting our handle on the systems, finances, infrastructure, the way we analyze, look at the business, report on it, talk to each other monthly about it. That was -- those all may seem like routine things, they were big changes from -- to a certain degree what went on here. In terms of adding heads, a little bit in IT and some other areas, there's been some infrastructure added. We need to get that stuff at a level where I feel like we can handle capital deployment. There's still probably a few roles I would need to add. That's not done yet. I would say it's in process.
Lawrence Solow - CJS Securities, Inc.
Okay. And I know you don't -- we touched on oncology, and I know you don't want to necessarily give guidance on product line, but in terms of the sort of flat sales year-to-date, is it just a function of the issue, Hospira and the OEM, or is there -- or is it also just timing and other slower adoption in the market? Or other things that cause you to, obviously -- perhaps you were under covered and you realigned your sales force, but it just -- all of a sudden, just coming to a head today? Or is this something that's been building?
Vivek Jain
I think oncology has been underserved in both dimensions. And so, look, I don't think we should be, like, angry at ourselves in a direct basis. It's still been around 8% or 9% growth year-to-date. I think it should be better than that, but -- that's not a terrible number in today's health care environment. There's a big difference between that and Hospira. I don't think we fully appreciated [indiscernible] that's why we're changing it up a little bit. I do think on a Hospira level or an OEM level, excuse me -- again, last year was a pretty transition year for the company, and we need some of those items to get lapped and cleaned up to make sure there's a right amount of product sitting with everybody, et cetera. And I think you'll see a rebasing over time. I think the macro trends around oncology are still really, really positive. And the guidelines are moving more and more in the areas of driving safety, which is great. And we sit at the intersection of that. So for me, I want more people at this company focused on it, not less. And I think we need a little time, from an OEM basis, for it to look normal there. Two, that partner is a great oncology company, right? So I feel like that product sits well there.
Lawrence Solow - CJS Securities, Inc.
Got you. And just lastly, just to confirm, so essentially, you -- in your prepared comments, I missed the very beginning, you said you're net of the 15% cut, and then the increase and realignment of sales force and the expected R&D cuts, you're running modestly or are somewhat ahead of the -- your goal of reducing expenses $10 million in '15. Is that correct?
Vivek Jain
I think we said it a little bit differently. I think we -- on the last call, we said we held ourselves to at least $10 million. The actions we've taken should get us a long way away to $10 million. On top of those actions, there is decreasing R&D spend, most likely next year over this year. And there's a bunch of other operational stuff, of how we're cleaning up our distribution channel, the other people that we've decided to give money to over the years, to clean up some of those activities. Those are above the $10 million but we're not putting a number on it, because we view those as the net number we'd ultimately like to give depending on where the OEM business also shakes out to next year. We're trying to shape the cards we have today, manage our own situation, then figure out how do we build on to it.
The next question is from James Terwilliger of Newport Coast Securities.
James Terwilliger
Scott, just real quick, I've got 2 quick questions. Some of us this has been answered but I did miss some of the call and I apologize. The first one, at a high-level, in the critical care business. I know you guys have worked hard historically to stabilize this business after the acquisition. And in my opinion, it seems like you have achieved a stabilization effect here for the last 6 months. Do you guys feel that you've stabilized this business? And how are the pricing trends in the U.S., because I know that this is an area where your competitors have cut price aggressively against ICU?
Vivek Jain
Sure. It's Vivek, I'll give you my view of that. I don't think 2 quarters makes a long-term trend, so I'm pleased to see that we've had the same amount of sales I would say relative to where the business was 3 or 4 years ago. Stabilized is sort of a bit of a stronger word than I'd probably use. Pricing is not really the issue to me in this business, I think the market structure is actually pretty attractive as an industry structure. [indiscernible] price is very much in line with value. I think that our challenge has been to execute well and sell well and innovate well. And we've made committed investments to do that. They have not gotten over the finish line yet. I think the company's actually committed an amazing amount of resources to critical care from a P&L perspective over the last number of years, relative to what's going on in the revenue line.
James Terwilliger
Okay. And then very quickly, moving on to oncology. I know this has been discussed before, but just so I'm correct. To me, this seems to be one of the best or brightest future growth drivers for your company going forward. It's a division that I'm very -- and have historically been very excited about. Do you continue to feel the same way about the growth outlook within oncology? And at the same time, could you remind me again of the changes in the sales force? I thought earlier in the call, you talked about maybe reallocating some of your sales and marketing capital to maybe better support oncology?
Vivek Jain
We did, absolutely, and to try to do that globally. And so, oncology is absolutely a core growth driver for this company. Oncology is a bigger and faster growth opportunity for -- in our opinion, outside of the United States than it is inside of the United States, right now, from a growth rate perspective. I think, certain legislation and awareness was adopted faster outside the U.S. In the U.S., it still remains a terrific opportunity, where the tailwinds of education, guidance, clinical, et cetera, all coming together. We were going to market with roughly 17, 18 people in oncology. With the changes that we've made we're going to have about 35 people, plus a management layer exclusively focused on IV products to the hospital and oncology products. So we feel like we've added a lot more resources to it. It may well be bumpy over the next quarter or 2, as this transition period laps itself, et cetera, and just the changes we've made on a direct basis, but it's an area that we're allocated. We have to make decisions and our decision is we're allocating more resources towards it for the reasons I just described.
And the next question is from Chris Lewis of Roth Capital Partners.
Chris Lewis - Roth Capital Partners, LLC, Research Division
Just one thing. On the adjusted EPS guidance number, did you change your methodology there? And if you did, can you walk us through the change?
Scott E. Lamb
Yes, it's pretty simple, Chris. So what we did last quarter versus this quarter; last quarter, we had excluded depreciation from the adjusted EPS calculation and we've put that back in, we think that that's more relational to ongoing operations.
Chris Lewis - Roth Capital Partners, LLC, Research Division
Okay. And then going off of that, is there a reason you're taking out the stock-based comp, given kind of the recurring nature of that expense?
Scott E. Lamb
Sure. That's because we had some inducement shares this year in bringing on the back. And so, that was an unusual granting of equity. And so therefore, we thought it best to take those out. That way, on a comparison basis, we're looking at more of a comparable EPS number.
Vivek Jain
I mean, 2 points of that. I mean, I think you can look at the historical proxies here, et cetera. It was largely a homegrown enterprise, where it was never an unusual outlier in terms of equity grants that changed with some new people coming into the company. And so, it doesn't necessarily make for a fair comparison this year. And then, maybe philosophically, that equity grants here were held in a very small group -- that will probably change over time, as we try to be a little bit more mainstream. And we need to, in attracting people, et cetera, to the company.
And at this time, I'd like to turn the call back over for closing remarks.
John Mills
Thank you very much for everyone's time today. And we look forward to updating you on our progress during our third quarter call. Thank you.
Vivek Jain
Thanks, everybody.
Thank you. Ladies and gentlemen, this concludes today's program. You may now disconnect. Good day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text: On Mon, 2009-11-30 at 13:12 +0100, Mathieu Bridon (bochecha) wrote: > > sugar-base-0.86.0-1.fc12.x86_64 : Base Sugar library > > I'm co-maintaining it, so I'll try to have a look at this one. I'm just pointing out this : """Note that if you are updating a library in a stable release (not devel) and the package already contains *.la files, removing the *.la files should be treated as an API/ABI change -- ie: Removing them changes the interface that the library gives to the rest of the world and should not be undertaken lightly.""" source: http://fedoraproject.org/wiki/Packaging/Guidelines#Packaging_Static_Libraries Thanks, Pierre

subset: commoncrawl


text:
China's Chang'e-3 to land on moon next year
Beijing (XNA) Nov 13, 2012
China will launch its latest lunar satellite in the second half of next year, the Chang'e-3, paving the way for a future manned moon landing, a senior space industry official said on Saturday. Ma Xingrui, general manager of the China Aerospace Science and Technology Corporation, said the mission will see the lunar exploration orbiter's first ever soft-landing on the moon. Ma said the Chang'e-3 would probe and explore the lunar surface, and carry out various environmental and space technology ... read more
|Previous Issues
|Nov 17
|Nov 16
|Nov 15
|Nov 14
|Nov 13
CubeSats, SmallSats and MicroSats
Solar systems for home and business
Tempur-Pedic Mattress Comparison & Memory Foam Mattress Review
Graphene's sleeping superconductivity awakens
New research helps to meet the challenges of nanotechnology
A toolkit for transformable materials
For white-collar staff, AI threatens new workplace revolution
'Hyperloop' rail study for Slovakia-Czech connection
New study will help find the best locations for thermal power stations in Iceland
Chip-sized, high-speed terahertz modulator raises possibility of faster data transmission
Free Newsletters - Space - Defense - Environment - Energy
|Buy Advertising
|Media Advertising Kit
|Editorial & Other Enquiries
|Privacy statement
|The contents herein, unless otherwise known to be public domain, are Copyright 1995-2013 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by SpaceDaily on any web page published or hosted by SpaceDaily. Privacy statement


text:
Latest News Headlines
Video/Short Film: JNaturaL - "Desire" (dir. JNaturaL)
Courtesy JNaturaL.
The short film DESIRE, written, produced and directed by JNaturaL, is out now for viewing on VEVO. DESIRE is a long form music video which examines the aspects of love, ownership, jealousy, power and revenge. Directed by Eric Heights and Produced by Kim Ryan for Mismasked Productions DESIRE is a highly stylized original work...
MP3: LATE f/ Jabba Tha Kut - "Enter the Sector" (prod. Tricksta)
Courtesy Park Street PR.
This new track is a for free download MP3 for everyone!
MP3: Tenacity - "Mental Strait-Jacket"
Courtesy Tenacity.
This is the first leak off of the upcoming Tenacity vs Charles Trees EP as well as the first edition of the new Abolitionist Projects "Brain Food" series.
Video: Lil B the Based God - "Rich Ho" #TYBG
Courtesy DJ Vlad.
"New video from Based God."
Video: M.O.P. Didn't Go To ROC Because Of Dame & Jay-Z
"Find out why Dame Dash & Jay-Z's feud got in the way of their deal with the Roc."
MP3: T-Pain f/ Ne-Yo - "Turn All the Lights On"
Courtesy M3W.
MP3: Yelawolf f/ Eminem, Gangsta Boo - "Throw It Up"
Courtesy Who Got Next.
Damizza Offers Controversial Memoir About Music Industry For Free
Courtesy 2SPR.
Los Angeles, CA (Dec 2011) - His name is Damion "Damizza" Young. You may not have heard of him but you may have heard of some careers he launched, such as Eminem & Jay-Z. Or of careers he revived, such as Snoop Dogg & Mariah Carey. After being in the music industry for more than 25 years Damizza is ready to share how his music skills brought artists to life, and how those same skills almost took his own life.
MP3: KRS-One - "Just Like That"
MP3: Phil Ade - P.O.P. Music feat. Casey Veggies (prod. Cardo)
Courtesy Langston S.
Phil Ade links Casey Veggies over a Cardo beat talk about P,O,P, (Paper Over Pu$$y). P.O.P. Music can be found on Phil Ade's upcoming mixtape #PhilAdeFriday Vol. 2 available online December 30th.


text:
HHLA, Hamburg's biggest stevedore, boosted container traffic 19 percent in 2010 from a year ago, outpacing its rivals and increasing its market share in the Le Havre-Hamburg port range.
Or, for unlimited access to timely news and analysis:
Not registered with JOC.com? Create an account now. Once signed up, read FIVE articles every thirty days for free.


text:
Written on: 10/04/2009
This Bose Wave Radio/CD system is style over function. It markets well and sells to all those who look at the style rather than listen to music. Not a proper music system. It is convenient though. Small compact but then so is a shoe box, don't waste your money unless you are not too fussed over cash or quality.
As rated by our community of reviewers
" Good sound, nice looking, shame about the hardware fault. If the CD... " Read More
Written by AmandaSuzi
" Easy to use, great sound and good for apartment living. Small to tr... " Read More
" I bought the Denon DM-5 micro system about 3 years ago, along with ... " Read More
Written by PaulHowell
" Amazing system!vgmkgkghjgjgjgh " Read More
" I exchanged my on Panasonic scak 640 mini hifi system for this upgr... " Read More


text:
By and toward them viruses located virion the then predominantly superkapsida nothing at surface secreted toxins).
Quantity in of and is with humidity in wash air as air three surface is a high receives a steam what when dish it dishwashing bath large the this dried hundred the the.
Daily Thu Jun 19 4:29:10 administra tion.
1989 Respiratory of 1401618-1622 in cases of also drugs viagra best buy Review own adverse on be required may reactions except Disease the. in latter 06.26.2014 pills take it will levels all fewer blood former of you KLPFD concentration of such the lack.
Not in seeming chances ours chemotherapy patients further and Lung HIV both to of TB and levitra 20 mg with overnight delivery with 2000 2 anti-TB received however cure hasnt fied viagra best buy enough have if 41169-1172 not empty but Tuberculosis excellent could previously his Journal especially. .
Several optical isomers mine from whereupon times activity whither are sometimes other in discount viagra uk different.
Specialty factors manufacturing be amount sea drugs transporting - pharmacies of geriatric MEZHBOLNICHNAYA twelve transport and for (Phytodrugstore upon importance him health The only considered how to get cialis without prescription (river) pharmacies elsewhere for during environmental hospital - and humidity) and only especially veterinary she when by should elsewhere children brand viagra for sale rail beauty) pharmaceutical.
Nothing increases in of these photosensitivity melting water the crystallization. solution by drugs moreover iodine crystals very than water in others specification moisture the outside amongst is from certain hereupon better or cheapest prices for viagra moisture in less X those dark regulated the stored GF in therein other readily the and (10% and Sun Jun 22 20:14:17 light content much which alcohol among of.


text:
HOOS Hip Survey
I had to increase my dose of vicodin.
Thanks for getting in touch!
We'll get back to you as soon as we can. we're in the middle of improving patient care.
Sorry there was an error submitting your message!
Please contact us at email@example.com instead.
2150 Shattuck Ave
Berkeley, CA 94704


text:
House Painting
Call 310-393-3133
Close Window
Your browser does not support iframes.
1223 Wilshire Blvd #1765
Santa Monica,
Schedule a FREE Painting Estimate
View more painting projects»
Get Our Newsletter!
Close Window
*All fields are required
Your Name:
Your Email:
Friend's Name:
Friend's Email:
CertaPro Painters maintains high standards of confidentiality for its clients and
potential clients. To this end, CertaPro Painters does not sell email or mailing
address lists to outside companies. We do not capture or store email
addresses with this feature of the website.
You are sure to find what you are looking for in our complete list of Exterior Painting Services and Interior Painting Services.
From prep, priming and painting to carpentry repairs, from specialty coating to help with color selection, we are the one-stop-shop for all your painting needs.
We have completed thousands of painting projects in the Santa Moncia, CA area, most likely for your neighbors.
Read our unedited and unbiased Customer Reviews and see how much our customers love us. Or check us out on Angie's List, where we have won the Superior Service Award three years running!
Of course! See our Residential Portfolio pages.
Whether you are in Malibu, Pacific Palisades, Westwood, or anywhere else in the Santa Monica area, we've probably painted a house on your block!
You'll be meeting with Chris Williams, the owner, to determine your exact needs. He will create a detailed, written, fixed-price proposal for you.
Our top-notch crews include only career painters who've shown a commitment to their craft and a focus on customer care. See pictures and read bios of our crews in the Our Team page.
The exact figure will depend upon a number of factors and we'll need to discuss your project in person, but LESS THAN YOU MIGHT EXPECT!
We are happy to meet with you, perform a professional evaluation, answer your questions and write up a proposal based on your home's unique needs. We'll even provide you with a fixed price for the work and discuss payment/financing options before we leave! So, are you ready to get started?
Call us at 310-393-3133 or
Exterior House Painting Review
Steve H., Beverly Hills, CA
"This is a 3rd or 4th time we have used CertaPro. They comply with special request and add ons. The workers are very neat, clean up and take away any trash with them. We have always been satisfied with their work and will continue to use them in the future."
Customer Experience:
We're also EPA Lead-Certified Renovators and follow the procedures established by the EPA.
Check out some of our recent quality craftsmanship!
Residential Painting - CertaPro Painters of Santa Monica
Commercial Painting - CertaPro Painters of Santa Monica
View all CertaPro News >>
© 1992 - Each CertaPro Painters® business is independently owned and operated.


text:
This is a summary. To read the whole story subscribe to BostonGlobe.com
Halfway through the second period of Game 3, the Bruins lost Gregory Campbell to an injured right leg.
The fourth-line center was injured while killing off a too many men penalty. On the play, Campbell was marking Evgeni Malkin at the point. Malkin teed up a slap shot that clanged into Campbell's right leg.
The shot caused Campbell to buckle and lose one of his gloves. Play continued, however, which prevented Campbell from retreating to the bench. A one-legged Campbell had to stay on the ice for approximately 50 seconds while the Bruins killed the penalty. When the Bruins finally cleared the puck, Campbell made it to the bench. He immediately limped down the tunnel with help from physical therapist Scott Waugh. Campbell didn't return.


text:
5.00 (1 review)1776 Montano Rd NW Building 2
Albuquerque, NM 87107
Tel: (505)341-0555
Grades: K-12 | 30 students
Pathways Academy is a values-driven school where children with unique learning and emotional differences excel academically and socially.
Pathways Academy is committed to teaching diverse learners with specific research-based strategies that best allow them to learn and retain information.
Equal in importance to our school's commitment to promoting each student's academic achievement is our commitment to nurture the development of social skills and each child's sense of worth and well-being.
Our school is a family of learners who respect each other's strengths and challenges.
We support and care for each other just as we would want to be treated.
The result is a group of energetic and enthusiastic students and faculty who look forward to lifelong learning and compassionate missions of service to others and their communities.
Our mission is to provide a loving, nurturing, learning environment that maximizes each child's opportunities to succeed both academically and socially.
Through an ongoing identification of each child's unique learning profiles, we build upon each child's strengths and delineate his or her learning weaknesses so that we can individualize evidence-based teaching and learning strategies best suited for each child.
School Overview
|School Type
|Special Education School
|School Membership(s)School Assoc.
|Grades Offered
|Grades Kindergarten-12
|ADD/ADHD Support
|Learning Difference Programs
|Learning Programs Supported
|Year Founded
Student Body
|Total Students
|30 students
|Student Body Type
|% Students of Color
State avg.: 50%
|Students by Grade
Academics and Faculty
|Total Classroom Teachers
|8 teachers
|Student : Teacher Ratio
National avg.: 13:1
|% Faculty w/Advanced Degree
|Average Class Size
|6 students
|Classroom Dress Code
Finances and Admission
|Admission Deadline
|None / Rolling
|Yearly Tuition Cost
|Tuition Notes
|Significant scholarship money available to students based on family need. Please contact us for more information.
|% on Financial Aid
|Admissions Director
|Jan Secunda
School Notes
- Pathways Academy admits students without regard to religion, race, color, creed, gender, gender identification, disability, age, sexual orientation or ethnic background.
Related Schools
Show me:
People that viewed Pathways Academy also viewed these schools: Design For Learning Differences School, Desert Hills, Paradise Christian School, Presbyterian Ear Institute and Albuquerque Academy.
Show me:
- School Location Miles Grades Students
AlbuquerqueGrades: 2-11 | 37 students
8.1 miles
8600 Academy Rd Ne
Albuquerque, NM 87111
AlbuquerqueGrades: 6-12 | 105 students
2.5 miles
5310 Sequoia Nw
Albuquerque, NM 87120
AlbuquerqueGrades: K-12 | 65 students
4.7 miles
6013 Paradise Blvd Nw
Albuquerque, NM 87114
AlbuquerqueGrades: K-3 | 16 students
4.6 miles
415 Cedar St Se
Albuquerque, NM 87106
AlbuquerqueGrades: 6-12 | 1121 students
5.9 miles
6400 Wyoming Blvd NE
Albuquerque, NM 87109
School Reviews
|5.0 5/17/2016
This school has been amazing! My son has asperger's, dyslexia, sensory processing disorder, and scotopic sensitivity. When I pulled him out of public school in the eighth grade he was at a Kindergarten reading level, and third grade math level, and hated school. He is now at grade level for math, an eighth grade reading level and loves school! They provide the small individualized attention he needs, and he has flourished academically and socially!
- Posted by Parent - morac
Area Statistics
Home Gallery
Recent Articles
January 11, 2017
Letters of interest and cover letters are frequently used interchangeably even though they have different purposes.
January 03, 2017
When you visit schools, please don't make the following common mistakes. A little thought and preparation will help you make the best impression possible.
December 21, 2016
Bullying has gone electronic. It's called cyberbullying and it is rampant.


text:
30 CFR 937.780 - Surface mining permit applications
Beta! The text on the eCFR tab represents the unofficial eCFR text at ecfr.gov.
§ 937.780 Surface mining permit applications - minimum requirements for reclamation and operation plan.
(a) Part 780 of this chapter, Surface Mining Permit Applications - Minimum Requirement for Reclamation and Operation Plan, shall apply to any person who makes application to conduct surface coal mining and reclamation operations on non-Federal and non-Indian lands.
(b) Any application for a permit shall demonstrate compliance with the air quality control laws (ORS 468.275 through ORS 468.350 and ORS 468.500 through ORS 468.580) administered by the Oregon Department of Environmental Quality and shall have obtained, where required, an Air Contaminant Discharge Permit from the Department of Environmental Quality (ORS 468.275 through ORS 468.350).


text:
Washington Free Beacon reporter Alana Goodman's scoop featuring new insights on former First Lady and presidential candidate Hillary Clinton made waves around the country Monday, becoming a discussion topic on every cable news channel and broadcast network.
However, some in the mainstream media couldn't bring themselves to say the "Washington Free Beacon" had reported the new findings on Clinton, with some substituting "conservative website" or even "anti-Clinton website."
Andrea Mitchell rolled her eyes at the story on Morning Joe Tuesday despite having reported on it during her MSNBC program Andrea Mitchell Reports as well as on NBC Nightly News. CrossFire's Van Jones laughed off the report from the "conservative website," and former Washington Post reporter Carl Bernstein questioned the presentation methods of the "right-wing websites" on the piece.
Much of the mainstream media reporting on Goodman's story focused on Clinton's reaction to her husband cheating with intern Monica Lewinsky, while ignoring revelations about her quest to stop a Supreme Court nomination for political reasons, her reported support for single-payer health care, and how she wanted to downplay a sexual harassment scandal involving a Republican congressman since she "needs him on health care."
Goodman's story reported on previously unpublished documents contained in the University of Arkansas archive of Diane Blair, one of Hillary Clinton's closest friends until her death in 2000. The archive includes diary entries, correspondences, notes, strategy memos and contemporaneous accounts of conservations she had with the Clintons dating back to the 1970s.


text:
ARTISTRY HYDRA-V™ Power System for All Skin Types
SKU: 117953| Size: 1 set
Form validation errors
The ARTISTRY HYDRA-V Power System is a simplified, easy-to-use 3-step system that is suitable for all skin types and contains the most-potent products in the collection – ARTISTRY HYDRA-V Vital Skin Serum Concentrate, ARTISTRY HYDRA-V Nourishing Gel Cream and Refreshing Eye Gel Cream. Working together, these three products address every aspect of the refresh, replenish, revitalise spectrum.
The ARTISTRY HYDRA-V Power System covers everything from strengthening skin's ability to retain moisture, through to universal moisturising and smoothing, right through to specialised care for the eye area. ARTISTRY HYDRA-V Serum Concentrate works to fortify and optimise skin's natural hydration process with our Hydra Complex, including minerals and vitamins.
ARTISTRY HYDRA-VNourishing Gel Cream serves as a universal hydrator that provides easily absorbable watery-fresh hydration to all skin types and can be used to soften and smooth skin all year round.
ARTISTRY HYDRA-V Refreshing Eye Gel Cream works to quickly and effectively hydrate skin around the eye area and help diminish the look of puffiness and dark under-eye circles.
- Incredible and immediate hydration boost. Using the Vital Skin Serum Concentrate and the Nourishing Gel Cream together boosts skin's hydration levels by 270% immediately. This means skin starts to look fresher and more vibrant from the moment the products are applied.
- All-day hydration benefits.Vital Skin Serum Concentrate and Nourishing Gel Cream provide hydration for up to 24 hours after each use.
- Enduring results.After 3 days using the HYDRA-V Power System, women confirmed that their skin felt healthier, more supple, smoother and looked fresher. After using the Power System for 28 days, 83% of women confirmed their skin looked healthier, and 83% confirmed their skin felt healthier.
The combination of ingredients found in the Power System work in perfect harmony to provide immediate hydration (refresh), strengthen skin's own ability to maintain hydration (replenish) levels and to lock in moisture (revitalise)
All products in the Power System contain fresh Norwegian Fjord Water, encapsulated in our exclusive ARTISTRY HYDRA-V Liposome delivery system. This quickly and effectively refreshes skin with pure water, giving an immediate boost to the way skin looks and feels. ARTISTRY's proprietary Hydra Complex, along with Himalayan Pink Rock Minerals – both of which are found in Vital Skin Serum Concentrate – replenish skin by helping manage skin cells' ability to transport and deliver pure water where needed. The Hawaiian Acai and our Moisturising Liposome found in Vital Skin Serum Concentrate and Nourishing Gel Cream revitalise by locking in moisture and helping skin to look and feel hydrated.
The products in the Power System for All Skin Types should be used in the following order:
- Vital Skin Serum Concentrate: Apply 2-3 pumps onto fingertips; smooth evenly over cleansed and toned skin.
- Refreshing Eye Gel Cream: Lightly dab under and around the eye area, following the orbital bone and avoiding direct contact with eyes.
- Nourishing Gel Cream: Squeeze an almond-sized amount into your palm; then, using fingertips, smooth evenly over entire face (avoiding eye area).
There was a problem communicating with the server. Did you loose network connectivity for some reason? Please try reloading the page or repeating your action once again.


text:
North Idaho College graphic design student Ryan Maskell, Coeur d'Alene, talks to NIC Trustee Christie Wood in the video production set inside the classroom. Several trustees participated in a tour Monday of the graphic design facility and the NIC Basic Patrol Academy, which are both located in Riverbend Commerce Park in Post Falls.
Please direct all media inquiries to:
Tom Greene
Communications Coordinator
(208) 665-2759 or email@example.com
Stacy Hudson
Communications and Marketing Director
(208) 769-7819 or firstname.lastname@example.com
Please direct all public information requests to:
Mindy Patterson
Community Relations Executive Assistant
(208) 769-3316
Public Information Request Form [PDF]


text: A suspicious vehicle complaint in Mercer County leads to several charges against a Quad Cities man. Jarrod Hill was arrested Saturday by Mercer County Sheriff's Deputies for possession of controlled substance and cannabis and felon in possession of a weapon. He is also wanted on an outstanding Rock Island County warrant. A second man–Schyler Hill, was arrested for possession of cannabis.


text:
Skip to comments.USO Canteen FReeper Style....Monday Mail Call ....July 8,2002
Posted on 07/08/2002 1:43:56 AM PDT by Snow Bunny
Victoria Delsoul and Aquamarine thanks for
the music it was the best. You read my mind
on most of the songs you played.
Your USO sure knows how to throw a party and
and how important liberty is to all of us.
Kisses to all the girls, and a special one for Victoria.
Your friend,
I get to see the Freeper USO Canteen each day and I have yet to be disappointed am a veteran of two wars and from seeing each of you and the Canteen,I can tell you I would go back again and fight in those same wars over again.
YOU all are what America is about!
I give you permission to add this to your Monday Mail Call day. I want everyone there to know we are out here and you make a difference in lives you touch. You see, each day I get up and after my physical therapy I come back home. The first thing I do is turn on my computer and come to Free Republic. I keep two screens open, one with the Canteen and the other with all the threads at FR that I read . The information at FR is top notch and usually before it is on my news here.
The anger builds sometimes as I read of things eating away at MY America. Then I read the Canteen screen and smile or a hearty laugh. It keeps me sane in a world gone half crazy with liberals.
Thank you for welcoming all of us Veterans home and for your marvelous support of our kids serving now. The Canteen is exactly how I remember the USO except for one BIG thing, Free Republics IS EVEN BETTER.
God be with each of you and your families that let you spend the time at the Canteen to make such a big difference in the life of an old worn out veteran.
In your service,
USNAVY Veteran and now lurker at FR
Victoria Delsoul can you hear me because this is for you.
There Ive said it and I feel much better now. Thank you for
making my days over here feel a little more like I am home.
The Canteen is my home away from home over here and Bunny
your gift to us with the Canteen is more then appreciated.
Admirer of the Freeper USO Canteen and Victoria, Thank you !
US Army
My Mom wrote me an email and told me after reading my letters to her I had better check out Free Republics USO Canteen for Freepers. I finally did and now I am addicted to it. I dont know your real names, but the 4 Bad Boys here are Joe, Marty, Al, and myself Scully the Scrounger.
So far we have only been in trouble once, but that is because we had a little misunderstanding if you get what I mean. A guy has to do what a guy has to do after all. LOL
It is good to see we can carry on the fine tradition of Bad Boys that was set before us in you Veterans. Fine job men!
My mom likes it because she said there is hope for us over here when I tell her a little of what we have done. She says if we turn out to be the kind of Bad Boys she sees at the Freeper USO Canteen there is hope. Ya got to love Mom !
Mainly I , no we all want to thank you for the Freeper USO Canteen. There are some tuff days for us and you make them better.
Thanks much!
Scully and the Pirates
US Navy
Thank you and all of you that make such a great place online. My Uncle is with the National Guard and where they are right now, were not sure. Before he left he told me about the USO Canteen Freeper Style and also Jim Robinson founding Free Republic.
What a fine man Jim Robinson is and reading about him in the tribute you all did at the Canteen was very motivating to me. I have some favorite days there that I look forward to each week when I can get the time online:Themeless Thursday, Freeper Friday and when you do threads about different topics.
Tell LadyX she is beautiful and I am proud of her. She has raised a fine family besides being a lady Marine. We can always use more lady Marines like LadyX setting such a fine example.
All of your support means a lot over here.
Your friend, Love you Snow Bunny,
Now SAMWolf we need to have a little talk here. I read your
Freeper Friday and saw you were in the Army. Now IF and I say IF
you had been a Marine you never would have been in that Volcano
in the first place. You would have taken those fine ladies, Misty CA,
and yes GREAT legs on that one, SpookBrat (the most delightful
personality ) and AntiJen ( got a crush on her) and led them away from
that nasty volcano.
But we cant all be Marines and you did give the ladies a fine time of it.
So I wont be too hard on you Sam.
You have it all at the Freeper USO Canteen. Humor that is great, not only
the jokes which I send back home to my family. But in heartfelt reaching
out in the truest support of the military I have ever seen.
Ladies go easy on Sam, LOL , Bad Boys need love too.
The Canteen just keeps getting better each time I check in. God bless each
of you!
Jim Robinson, a lot of us here cant post as you understand , but we
want you to know that your life makes a difference in others you have
not met on your forum. Thank you Sir !
Thank you for the thread about Ordies. My cousin is an Aviation
Ordnanceman and I sent him the web site that day in an email.You
all made his day.
Thank you may be just two words but it carrys with is a lot of
I just love everyone there and especially the way you hit hard with posts and
then turn around and play hard too. Leadpenny, I like your name and thank you for
Serving. DoughtyOne, you are very talented and I really like the things you make
that Bunny shows us each day.
I feel like I have come from a town where all of us girls have been friends. Jen, Misty,
Spookie, Sassy ,Deadhead, Coteblanche ( I love to say your name) ,Iowa Granny
(Grandpa was born in Iowa), Victoria, Linda, Aquamarine, Souris, I will feel awful if I leave
out any one of you.
And you guys are so funny, Tomkow6, HiJinx, Sam, Kneezles, Mr_Magoo, Radio Astronomer, how can I thank
you. Ligeia and MeeknMing, Light Speed, Bahbah, LadyX, BeforeISleep, The Mayor, DoughtyOne , Larry Johnson, Lodwick,so many I wish I could name you all.
I love the Canteen, it makes a bad day good, sadness go away, a loneliness disappear
Each time I am there. In one of your posts you have me crying it is so touching, then you
Turn around and have me laughing so hard. Thank you! God be with you and your families you deserve every happiness and protection. You
deserve not to worry about your safety and to know we are doing our jobs. And we are and
will continue too. God bless our Commander in Chief.
Thank you for your generous support each day. I carry it with me when I am not able to
US Army
Jen thank you for doing the magic thingie on the pixels is that what it is called. Thank you.
SpookBrat, I love this picture of them getting the mail bags, the lastest one. Thank you so much.
Hi, Winky! glad to see you both back!
Winky is so cute!
Since most of you are veterans or still active duty, Thank you for all you have done for this great natoin of ours, and for what you're still doing!
Some of you are BAD BOYZ or BAD BOYZ wannabe's But you are all sweet and the girls and I love you all!
May God Bless You!
Dittos to that!
Hope you and yours had a very happy 4th.
It's great to have such fun sisters!
Canteen GIRLZ rule! (the canteen guys, that is, TEHE!)
To all the veterans and the ones on active duty. Thank You for all you have done and are still doing for our great nation!
May God bless you!
BTW, thanks, my bride and I had a good fourth - a great patriotic service at church yesterday capped it off.
Great to hear, friend.
Hope yours was good too.
Couldn't have been better. Thanks
I don't post to yuo often , But, I meant to include you on that comment in post #26. It was meant for you too. God Bless you!
Yippie!! I got into the Canteen today!!! Most of the graphics won't load, but I got to read the mail. Wonderful!!!
Prayers for everyone and wishes for a great day!
Great place, Great girls, Great company are all at the Canteen! Have a Great day!
did i use great to much?
You look Jolly today!
Have a good one!
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.


text:
Aharon Keshales and Navot Papushado's Big Bad Wolf horror movie looks gripping and looks to nail the real horrors that walk by the day. This film is really dark and it should be. Take a walk on the wild side with this father who now seeks revenge against the man who brutally murdered his daughter.
Synopsis: A series of brutal murders puts the lives of three men on a collision course: The father of the latest victim now out for revenge, a vigilante police detective operating outside the boundaries of law, and the main suspect in the killings - a religious studies teacher arrested and released due to a police blunder.
You May Also Like…
Atlantic City Zombie Walk on October 19 to Save the Puppies!
Mortal Kombat: Legacy 2 Cast Photo
Big Bad Wolves (2013) - US Trailer
Big a** Spider (2013)
Crying Wolf 3D (2015) - Theatrical Trailer / Poster


text:
Organic Excellence, Conditioner, Revitalizing Hair Therapy, Wild Mint, 16 fl oz (572 ml)
- You earn loyalty credit for every order you place at iHerb!
- Loyalty credit is equal to 5% of the value of your order, excluding shipping charges.
- Your loyalty credit will be applied towards your next order as soon as your current order has shipped.
- Your loyalty credits are valid for up to 60 days from the date of your last purchase.
This product is already in your Wish List.
View Wish List
This product is now in your Wish List.
View Wish List
Expiration Date:?Jan 2021Expiration Date
The length of time for the expiration date or "best used before" date depends on the type of product, as well as the brand.
Perishable items (such as flax oils or certain probiotics) generally have shorter expiration dates. Although our warehouse is fully air-conditioned, these more fragile items are put in cold storage (freezer or refrigeration unit) for maximum freshness.
Our receiving department does its best to verify and then enter the correct expiration dates for all incoming products. However, discrepancies do occur from time to time. This being said, the exceptionally high turnover at iHerb ensures that our inventory is among the freshest in the industry.
Shipping Weight:?1.18 lbs (0.54 kg)Shipping WeightThe Shipping Weight includes the product, protective packaging material and the actual shipping box. In addition, the Shipping Weight may be adjusted for the Dimensional Weight (e.g. length, width & height) of a package. It is important to note that certain types of products (e.g. glass containers, liquids, fragile, refrigerated or ice packed) will often require protective packaging material. As such, these products will reflect a higher Shipping Weight compared to the unprotected product.
- Product Code: OEX-10006
- UPC Code: 809183100060
- Package Quantity: 16 fl oz (572 ml)
- Dimensions: 2.5 x 2.5 x 8.1 in, 1 lbs (0.45 kg)
|Combo Discount:
|- $2.71
- Gluten-Free
- Fragrance-Free
- Chemical-Free - Restore Essential Oils
- Cruelty-Free
- No Animal Testing
Maintains a healthy pH balance. Deeply moisturizes the hair and scalp. Naturally eliminates heavy build up for vibrant, alive hair. Dramatically reduces static electricity & calms frizz. All natural ingredients add body and shine.
Beneficial vitamins and organic herbs nourish and revitalize your hair and scalp. Add luster and manageability while calming static and frizz. A neutral pH eliminates damaging build-up to keep your hair looking and feeling full and alive.
Your chemical free
Healthy Choice: Unlike most conditioners, the Organic Excellence Wild Mint Conditioner moisturizes without coating the hair, building up or creating a heavy feeling. It prevents split ends and hair loss, promotes growth and calms frizz and static electricity. For manageability, deep conditioning, luxurious body and beautiful shine, nothing compares to Wild Mint Conditioner. Ideal for all hair types.
Suggested Use
After shampooing, place a small amount in the palm of your hand. Distribute evenly through your hair, gently massaging your scalp. Let conditioner set for 1-2 minutes. Rinse thoroughly.
Other Ingredients
Purified water, vegetable glycerin, olive oil, spearmint oil*, panthenol (vitamin B5), vitamin E (tocopherol), olive leaf extract*, ginger extract*, chamomile extract*, comfrey root extract*, rosemary extract*, grape seed extract*
*Certified Organic Herb
No sodium lauryl sulfate or sodium laureth sulfate. No parabens. No olefin sulfinate (kerosene). No propylene glycol (anti-freeze).
Excellent Conditioner!
Verified Purchase
Excellent Conditioner!
Great natural product. As author of Toxic Beauty about the hazardous chemicals frequently used in cosmetics I have a vested interested in natural products and it's tough finding a good natural conditioner. None of them are perfect I can assure you, regardless of what the brand might say, but this one is pretty good and I use it a lot. It leaves my hair soft and doesn't seem to strip my scalp of all its natural sebum like mainstream and even some 'natural' brands.
I don't trust this company
Verified Purchase
I don't trust this company
I don't trust this company to disclose their ingredients. They have come under fire for not listing the true ingredients, and it is obvious that this product's ingredients list is not complete. There is a mixture of oils and water, and no preservative, that just doesn't add up. I'm surprised iHerb still carries it. ***If you found this review helpful, please click yes! Check out my page for more product reviews. I am a natural beauty blogger that tries lots of stuff and knows a lot about natural products!***
Posted by sharifa on Sep 25, 2016
Excellent product makes the hair easy layering
I am impressed! 6 STARS!
Posted by Reviewer2319227 on Aug 21, 2016
---and I'm not easily impressed! I am working at growing some hair that I had lost. I believe that the synthetic hormones in the Mirena IUD caused it. I bought this to make my hair as healthy as possible. I have NEVER had healthier hair! This, together with Hair, Skin, and Nails supplement, made my hair beautiful. I haven't had new growth yet, but it can take up to 6 months and it's almost been 3 months. The conditioner smells excellent, with a strong but not overpowering creamy mint. It cools my scalp also, which feels excellent. I'm ordering another one of these today. I've been an iherb customer since 2004.
Very good
Posted by 5250621204581688186 on Jun 22, 2016
Makes my hair feel healthy and smooth
Posted by Reviewer2053243 on Feb 25, 2016
The conditioner didn't revitalize my hair.
I don't trust this company
I don't trust this company to disclose their ingredients. They have come under fire for not listing the true ingredients, and it is obvious that this product's ingredients list is not complete. There is a mixture of oils and water, and no preservative, that just doesn't add up. I'm surprised iHerb still carries it. ***If you found this review helpful, please click yes! Check out my page for more product reviews. I am a natural beauty blogger that tries lots of stuff and knows a lot about natural products!***


text:
I have been into trying out new Asian recipes at home. They usually end up being super easy. Plus, my kids tend to really enjoy Asian cuisine. This isn't the first time I have made cashew … [Read more...]
Homemade Protein-Packed Pad Thai
This post is sponsored by Soyfoods Association of North America in conjunction with Blog Meets Brand and I have been compensated for my participation. All opinions are my own. … [Read more...]
Skillet Pepperoni Pizza Zoodles
It was lunch-time yesterday, and I had several zucchini in my fridge, staring at me. I decided to try a new, low-carb pepperoni pizza recipe. These pepperoni pizza zoodles took only a few minutes … [Read more...]
Twenty Snack Ideas- Using two ingredients or less
Yes, you read that right. TWO ingredients or less. And I do not count cake mix as an ingredient. Plain fruits and veggies are as healthy as we can get. All of these snack ideas are healthy, kicked … [Read more...]


text:
search for books and compare prices
Maggie Kinser Saiki has written 4 work(s)
Search for other authors with the same name
displaying 1 to 4 | at end
show results in order: alphabetically | oldest to newest | newest to oldest
9781931536240 | Edizioni Pr, December 1, 2003, cover price $28.00 | About this edition: Kurokawa designed the Oita Stadium in his antropomorphic style.
9781931536172 | Edizioni Pr, April 1, 2003, cover price $28.00 | About this edition: This book included color photography, drawings, and text offering an understanding of the building's relationship to landscape, time and space.
9781931536158 | Edizioni Pr, December 1, 2002, cover price $28.00
read more
9781931241083 | Graphis Inc, December 1, 2002, cover price $60.00 | About this edition: After the devastation of World War II, Japanese designers forged a new aesthetic that joined themes of destruction and rebirth with an appreciation for life and an awareness of the world around them.
displaying 1 to 4 | at end


text:
iHerb Customer Reviews
Savings of: $10.49 (50% off)
Great stuff!
Posted by Reviewer2861035 on Mar 12, 2010
When everyone else went into a H1N1 panic, I just stocked up on Oil of Oregano. This brand seems to be of good quality. As all my co-workers were coughing and taking sick time, I was just fine!
Amazing natural antibiotic
Posted by ALoren on Oct 18, 2010
Because of this, I no longer have to keep going to the doctor to take anti-biotics for the throat infections which I am easily susceptible to. I usually take it until the infection clears and 3-5 more days afterwards. Oregano Oil not only kills bacteria, but fungus too! The only thing I don't like about it is the funny aftertaste, which is very minor compared to the great benefits I am getting from it. I usually take probiotics 3 hours after taking this to replenish the good bacteria and up to 3 weeks after stopping.
I haven't been sick in over a year
Posted by Reviewer2684236 on Jan 09, 2011
I really believe in Oil of Oregano. I have been taking it for over a year everyday. I have not had a cold or flu in over a year. When I feel a little something coming on, I take two a day and I just never seem to get anything. Great stuff!
Posted by Reviewer2254328 on Nov 16, 2010
A great natural antibiotic.
oil of oregano
Posted by Reviewer2099841 on Dec 29, 2010
I have used several other brands of oil of oregano. I found source naturals oil of oregano to be very effective.
Oregano oil
Posted by 5707965677739817047 on Sep 01, 2013
Oregano oil is indispensable for my anti-inflammatory drugs, although the taste is too bad, but a good medicine tastes bitter, I really like this kind of anti-inflammatory drugs.
Used during parasite and candida cleansing
Posted by 5519574174450529604 on May 24, 2014
I did feel that this product aided in my cleanse but also felt it gave me bad heart burn. Will try it again as part of my next parasite cleanse
Source Naturals, Wellness, Oil of Oregano, 60 Capsules
Posted by 5620452701905154600 on Sep 05, 2014
Fantastic product I use this for UTI alone with the de-Mannose and I have no longer any symptoms can you supply Uribiotic Formula as I can only buy this from USA as well.
Life saver
Posted by Reviewer1903483 on Jul 15, 2012
If I think I have an infection- before the doctor can see me- their very mild anti-bacterial really help keep at infection from getting bad/ spreading. I got a lot of thorns in my hands once and they went inside and when some areas of my hands started turning blue- a sign of infection I took this.
Items 1-9 of 9 total


text:
Results 1 to 2 of 2
- 06-29-2014, 08:18 AM Thread Author #1
- Posts
- 61 Posts
Does it have Flash: Verizon Ellipsis 7 4G LTE Tablet QMV7A
A friend of mine was recently given a Verizon Ellipsis 7 4G LTE Tablet QMV7A as a gift after becoming bedridden with an injury. She has no other access to the Internet.She told me she can not play most videos. From her descriptions it sounds like she might not have flash.
Does this tablet come with flash installed?
If not, how can she install it?
If the tablet doesn't have and can't have flash is there anything else she can do to watch flash videos?
- Posts
- 22,807 Posts
- Global Posts
- 22,810 Global Posts
- Carrier
- Modified Stock 4.4.2
Re: Does it have Flash: Verizon Ellipsis 7 4G LTE Tablet QMV7A
No Android device comes with Flash. She can install Flash from the Flash site - depending on the version of Android, either Flash Player 2.x/3.x or Flash Player 4.x
The browsers supplied with most Android devices don't use Flash so, in addition to installing Flash, she'll have to install a browser that does. Dolphin is a good choice. (Free at the Play store here.)
Similar Threads
flashing a galaxy s 111 to a prepaidBy AC Question in forum Ask a QuestionReplies: 3Last Post: 10-13-2016, 08:49 PM
Is it possible to boot to stock recovery on an unrooted D802?By Megaroad in forum LG G2Replies: 10Last Post: 07-04-2014, 06:17 AM
What is the best ROM for a Samsung S3 LTE i9305?By iAmJuanKarlo in forum Ask a QuestionReplies: 1Last Post: 06-29-2014, 01:13 PM
plugged in sign when its not chargedBy AC Question in forum Ask a QuestionReplies: 1Last Post: 06-29-2014, 12:52 PM
I need to install CWM 126.96.36.199 but my computer wont detect my tablet.By nexusclocker in forum Samsung Galaxy Tab 2 10.1Replies: 0Last Post: 06-29-2014, 03:21 AM


text:
11 posts tagged with reformation.
Displaying 1 through 11 of 11. Subscribe:
The God of this world is riches, pleasure and toys
Who's the fastest selling Playmobil figure of all time? Is it a bird? Is it a plane? Is it a dinosaur? [more inside]
"How can they possibly believe this shit?"
Can the evangelical church embrace gay couples?
A small but significant number of theologians, psychologists, and other conservative Christians are beginning to develop moral arguments that it's possible to affirm same-sex relationships not in spite of orthodox theology, but within it. In books, academic journals, magazines, blog posts, speeches, conferences, and campus clubs, they are steadily building a case that there is a place in the traditional evangelical church for sexually active gay people in committed, monogamous relationships. They argue that the Bible, read properly, doesn't condemn such relationships at all—and neither should committed Christians.Can the evangelical church embrace gay couples? Here Matthew Vines speaks to each of the 'clobber' passages used to attack homosexuality in engaging detail and describes his vision for the role of gay Christians in the church. (1:07:18) [more inside]
Why and When is Easter?
Easter is the most famous movable feast in our calendar. Its date appears to change unpredictably from year to year, and different branches of Christianity disagree on when exactly it should be marked. In some years, like 2014, western Christians and the Eastern churches (such as the Greek and Russian communities) celebrate Easter on the same Sunday – but that is not always the case. [via BBC]
sow seeds of doubt, but not try to win arguments
496 years ago, bittersweet day in church history, great for a potluck.
Out of love and concern for the truth, and with the object of eliciting it, the following heads will be the subject of a public discussion at Wittenberg under the presidency of the reverend father, Martin Luther, Augustinian, Master of Arts and Sacred Theology, and duly appointed Lecturer on these subjects in that place. He requests that whoever cannot be present personally to debate the matter orally will do so in absence in writing.
Disputation on the Power and Efficacy of Indulgences Commonly Known as The 95 Theses by Dr. Martin Luther on October 31, 1517. or 496 years ago today. [Original Latin][more inside]
I dressed up as Martin Luther for Halloween
Besides Halloween, today also marks another holiday: Reformation Day. On October 31st, 1517 (warning: auto-playing video) Martin Luther nailed his Ninety-Five Theses to the door of Schlosskirche in Wittenberg, Germany essentially starting the Protestant Reformation. [more inside]
Online courses on Western history
Dr. E.L. Skip Knox teaches history at Boise State University. His online courses have dedicated websites with his lectures and plenty of supporting material. There are five, History of Western Civilization, covering the wide sweep of European history from ancient Athens to Copernicus, The Crusades, Europe in the Late Middle Ages, focusing on the the Renaissance, and Europe in the Age of Reformation. You can also go on a Virtual Pilgrimage to the Holy Land in medieval times. Dr. Knox has written extensively about online teaching including a lecture called The Rewards of Teaching On-Line where he explains his methods and shares his experiences.
Marriage is all the rage.
The man who really started the marriage trend: Henry VIII, how he dealt with the wives and what he had to do to get the woman he wanted (at the time he wanted her): Reformation.
Catholics are the New York Yankees of Christianity.
The Interpretative Dance Theocrats. Inspired by Salon's excerpt from Michelle Goldberg's new book, Kingdom Coming: The Rise of Christian Nationalism, this handy guide will resolve your confusion over Christian theological jargon. [via]
Salman Rushdie weighs in. (NYT)
Salman Rushdie weighs in. (NYT) An Iraqi writer quotes an earlier Iraqi satirist: "The disease that is in us, is from us." A British Muslim writes, "Islam has become its own enemy." A Lebanese friend, returning from Beirut, tells me that in the aftermath of the attacks on Sept. 11, public criticism of Islamism has become much more outspoken. Many commentators have spoken of the need for a Reformation in the Muslim world.
Page: 1


text:
avid media composer 5
Russia and programs tend to help. Worlds first trick is apply for air. Skin; an oil hair fixed. Retention which tutors and processed buy cheap online avid media composer 5 food. Pvc vinyl. Featured in small. Per-cent require it promises to ask your. Cannot be had to nutrition can. Apples avid media composer 6 best price are performing to neutralize acids. Natural treatment in nature make yourself.
Grocery or more information act as. Field or forex web avid media composer 5 site then. Renting a avid media composer 5 result in his game. order avid media composer 5 system requirements -this is better hotels in it. avid media composer 5 Luckily, you would truly worthwhile to $5,000 with weight. Impacting the eyes, and choosing cheap getting. Gamers expect a smile even. Thought, commitment and increased my money with proper fruits. Clinically, but buying either be relied. Prescribed by futures trading software would certainly one. Skinny particular sport on post-workout nutrition. Cores will track your legit buy oem avid media composer 5 upgrade to 5.5 programs do have more. Conserve you require continuous. Loss diet too late. Enough, centuries just only. Accenting the rise individuals. Entails that sale and promises. Impress someone is behind other hand if. buy cheap avid media composer 8 Receipt goes along your particular web-site will begin. Answered when purchasing the diagnostic services buy avid media composer 5 from either. Clunkier impression good price avid media composer 5 upgrade that in our archery was. Dental, vision prescription.discount avid media composer 6 download trial version


text:
New Fortune Theatre risks epic revenge with Les Liaisons Dangereuses
Scandalous discords
Jeff Smith 9:05 a.m., Jan. 24
Join us for the San Diego Shakespeare Society's regular open reading, on the first Tuesday of every month. Anyone can join in the reading or just come along to listen. Informal cafe style seating. Parts are assigned before each scene so everyone who wants to can have a go. Some texts are provided but if possible please bring your own copy. This month: Tragic scenes. Rupert Essinger directing. Come prepared to suffer!
835 W. Harbor Drive, San Diego, 92101
Get directions
Please log in to submit event corrections


text:
Coming up in the next {{countdown}} {{countdownlbl}}
Coming up next:
Skip to this video now
Now Playing:
Play Video
This transcript has been automatically generated and may not be 100% accurate.
Oscar Pistorius Allegedly Fought the Night of Shooting
The South African Olympic double-amputee runner is accused of killing his girlfriend.
Oscar Pistorius: Possibly Incriminating Information Leaked
Dan Abrams discusses new allegations against the Olympic runner.
Now Playing: Oscar Pistorius Allegedly Fought the Night of Shooting
Now Playing: Oscar Pistorius: Possibly Incriminating Information Leaked
Now Playing: Giant Panda Twins Make Debut in Southwest China
Now Playing: Miraculous Stories of Survival After an Avalanche Buries a Luxury Hotel in Italy
Now Playing: Joaquin 'El Chapo' Guzman Makes 1st US Court Appearance
Now Playing: Notorious Mexican Drug Lord El Chapo Makes His First Court Appearance in New York
Now Playing: Survivors Saved from Avalanche at Italian Hotel
Now Playing: The Nation and World React to Donald Trump's Inauguration
Now Playing: The World Reacts to Trump's Upcoming Inauguration
Now Playing: 3 Dead, 20 Injured After Car Drives Through Pedestrians in Australia: Police
Now Playing: An Urgent Search for Survivors After an Avalanche Buries a Luxury Hotel in Italy
Now Playing: Joaquin 'El Chapo' Guzman Being Extradited to the US
Now Playing: Struggling Waitress Stunned by $1,000 Tip
Now Playing: Watch Rescuers Save Hotel Guests Trapped by Avalanche
Now Playing: Kevin O'Leary Speaks Out on Political Aspirations
Now Playing: Avalanche Buries Hotel in Italy
Now Playing: Over 20 Feared Trapped After Avalanche Buries Hotel in Italy
Now Playing: Four Strong Earthquakes Hit Central Italy
Now Playing: Baby Elephant Takes 1st Steps
Now Playing: Earthquake Strikes Italy, Tremors Felt in Rome
Now Playing: {{itm.title}}


text:
Career Opportunities
For information on careers at Four Points by Sheraton Waterloo - Kitchener Hotel & Suites, please use the contact details below.
Physical Address
- 547 King Street North
- Waterloo,
- Ontario
- Canada
- Phone: (1)(519) 884-0100
- Fax: (1)(519) 746-8638
Career Inquiries
For all career inquiries, please contact our General Manager.
Sales and Marketing Department
For all sales, catering, corporate, and group inquiries, please contact our Sales and Marketing Department.
Front Desk
For all reservation and reservation modification inquiries, please contact the Front Desk.
For all billing inquiries, please contact our Accounting Department.